Relay, Ramucirumab Plus Erlotinib (Ram Plus Erl) Versus Placebo Plus Erlotinib (P Plus Erl) In Untreated Egfr Mutated Metastatic Non-Small Cell Lung Cancer (Nsclc): Exposure-Response Relationship
Annals of Oncology(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要